US regulatory status: approved.
pharma · Anorectal Disorder · Localized Primary Osteoarthritis of Both Hips (Diagnosis)
Chia Tai Tianqing
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Chia Tai Tianqing drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Lianyungang, CN HQ
366 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Lianyungang, CN
- Employees
- 366
- Programs
- 11
- Drugs
- 15
- Patents
- 0
Chia Tai Tianqing pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chia Tai Tianqing drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Chia Tai Tianqing's portfolio.
-
efungumab
Antiinfectives for systemic use (J02)Antiinfectives for systemic use (J02) compound in Chia Tai Tianqing's portfolio. Molecular target: Heat shock protein 90 homolog.
- Target
- Heat shock protein 90 homolog
- Mechanism
- Heat shock protein 90 homolog inhibitor
-
hepatitis b vaccine (recombinant dna)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Chia Tai Tianqing's portfolio. Molecular target: Surface antigen (HBsAg).
- Target
- Surface antigen (HBsAg)
- Mechanism
- Surface antigen (HBsAg) vaccine antigen
-
lidocaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to Chia Tai Tianqing in public FDA and regional records.
-
risperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
Development asset linked to Chia Tai Tianqing in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 2.
- Target
- Carbonic anhydrase 2
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
Development asset linked to Chia Tai Tianqing in public FDA and regional records.
-
Development asset linked to Chia Tai Tianqing in public FDA and regional records.